Lupin unveils schizophrenia drug Lurasidone Hydrochloride in US
Mumbai: Global pharma major Lupin Limited has announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg in the United States.
The product is a generic equivalent of Latuda Tablets of Sunovion Pharmaceuticals, Inc.
Lurasidone is indicated for the treatment of symptoms of schizophrenia in adults and children 13 years of age and older.
Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (RLD Latuda) had estimated annual sales of USD 4.2 billion in the U.S. (IQVIA MAT December 2022).
Medical Dialogues team had earlier reported that the company had launched Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg in the United States.
Read also: USFDA nod to Lupin Glycopyrrolate Injection
Lupin is a transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 8.7% of its revenue in research and development in FY22. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
